Literature DB >> 24831325

Topical pharmacotherapy for skin cancer: part II. Clinical applications.

Giuseppe Micali1, Francesco Lacarrubba2, Maria Rita Nasca2, Salvatore Ferraro2, Robert A Schwartz3.   

Abstract

The purpose of the paper is to provide an in-depth, evidence-based analysis of the clinical use of topical treatments for skin cancer. A comprehensive review of topical drugs has been performed, including 5-fluorouracil, imiquimod, diclofenac, ingenol mebutate, retinoids, resiquimod, piroxicam, dobesilate, and betulinic acid. The evaluated studies were rated according to their level of evidence level (I-V), as indicated by recent guidelines for evidence-based medicine, The Oxford 2011 Levels of Evidence. Therapeutic response is generally related to tumor type, extent, and localization, and also to patient compliance. Careful patient selection is required in order to achieve the desired goal of complete tumor clearance.
Copyright © 2014 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.

Entities:  

Keywords:  Bowen disease; Paget disease; actinic keratosis; basal cell carcinoma; erythroplasia of Queyrat; lentigo maligna; melanoma; skin cancer; squamous cell carcinoma; topical treatment

Mesh:

Substances:

Year:  2014        PMID: 24831325     DOI: 10.1016/j.jaad.2013.12.037

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  18 in total

Review 1.  Lentigo maligna and lentigo maligna melanoma: contemporary issues in diagnosis and management.

Authors:  Karen L Connolly; Kishwer S Nehal; Klaus J Busam
Journal:  Melanoma Manag       Date:  2015-05-18

Review 2.  Talimogene laherparepvec (T-VEC) for the treatment of advanced melanoma.

Authors:  Douglas B Johnson; Igor Puzanov; Mark C Kelley
Journal:  Immunotherapy       Date:  2015-06-22       Impact factor: 4.196

Review 3.  Basal Cell Carcinoma: A Narrative Review on Contemporary Diagnosis and Management.

Authors:  Piyu Parth Naik; Munaf B Desai
Journal:  Oncol Ther       Date:  2022-06-21

4.  Complexation of 5-Fluorouracil with β-Cyclodextrin and Sodium Dodecyl Sulfate: A Useful Tool for Encapsulating and Removing This Polluting Drug.

Authors:  Ana M T D P V Cabral; Ana C G Fernandes; Neuza A M Joaquim; Francisco Veiga; Sara P C Sofio; Isabel Paiva; Miguel A Esteso; M Melia Rodrigo; Artur J M Valente; Ana C F Ribeiro
Journal:  Toxics       Date:  2022-06-01

5.  Topical imiquimod as a neo-adjuvant chemotherapy for cartilage salvage in the treatment of nodular basal cell carcinomas of the head and neck.

Authors:  Saurabh Singh; M Bandhala Rajan; Abhishek Bhardwaj
Journal:  Indian J Dermatol Venereol Leprol       Date:  2021 May-Jun       Impact factor: 2.545

Review 6.  Adjuvants: Classification, Modus Operandi, and Licensing.

Authors:  Juliana de Souza Apostólico; Victória Alves Santos Lunardelli; Fernanda Caroline Coirada; Silvia Beatriz Boscardin; Daniela Santoro Rosa
Journal:  J Immunol Res       Date:  2016-05-04       Impact factor: 4.818

7.  Anti-cancer activity of ZnO chips by sustained zinc ion release.

Authors:  Seong-Hee Moon; Won Jin Choi; Sik-Won Choi; Eun Hye Kim; Jiyeon Kim; Jeong-O Lee; Seong Hwan Kim
Journal:  Toxicol Rep       Date:  2016-03-19

8.  Factors influencing response to ingenol mebutate therapy for actinic keratosis of face and scalp.

Authors:  Nevena Skroza; Ilaria Proietti; Nicoletta Bernardini; Veronica Balduzzi; Alessandra Mambrin; Anna Marchesiello; Ersilia Tolino; Sara Zuber; Giuseppe La Torre; Concetta Potenza
Journal:  World J Clin Oncol       Date:  2017-10-10

9.  Topical Colchicine Gel versus Diclofenac Sodium Gel for the Treatment of Actinic Keratoses: A Randomized, Double-Blind Study.

Authors:  Gita Faghihi; Azam Elahipoor; Fariba Iraji; Shadi Behfar; Bahareh Abtahi-Naeini
Journal:  Adv Med       Date:  2016-09-05

Review 10.  Updates on the Management of Non-Melanoma Skin Cancer (NMSC).

Authors:  Artur Fahradyan; Anna C Howell; Erik M Wolfswinkel; Michaela Tsuha; Parthiv Sheth; Alex K Wong
Journal:  Healthcare (Basel)       Date:  2017-11-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.